

1FW Box 59

TRANSMITTAL LETTER
(General - Patent Pending)

Docket No.
87792.065605

In Re Application Of: Boneham et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/537,852	December 12, 2005	Unknown	23,469	1646	7267

Title: **PEPTIDE PRESENTATIONS FOR HUMAN IMMUNODEFICIENCY VIRUS VACCINES**

COMMISSIONER FOR PATENTS:

Transmitted herewith is:

Submission of Papers Previously Filed in the U.S. Patent and Trademark Office in Response to a Notification of Defective Response (57 pages) including Exhibit A which is a copy of previously submitted Response to Notification of Defective Response (50 pages and one computer readable 3.5" diskette) and Exhibit B which includes a Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures and Withdrawal of Previously Sent Notice

in the above identified application.

- ☒ No additional fee is required.
- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **10-0223** as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.



Signature

Dated: August 4, 2006

Robert D. Lott, Esq.
Reg. No.: 28,441
JAECKLE FLEISCHMANN & MUGEL, LLP
190 Linden Oaks
Rochester, New York 14625-2812
Telephone: (585) 899-2930
Facsimile: (585) 899-2931

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

8/4/06
(Date)





Signature of Person Mailing Correspondence

Elizabeth Kinsley

Typed or Printed Name of Person Mailing Correspondence

cc:

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)			Docket No. 87792.065605	
Applicant(s): Boneham et al.				
Application No. 10/537,852	Filing Date December 12, 2005	Examiner Unknown	Customer No. 23,469	Group Art Unit 1646
Invention: PEPTIDE PRESENTATIONS FOR HUMAN IMMUNODEFICIENCY VIRUS VACCINES				
				
I hereby certify that this <u>Submission of Papers Previously Filed...Notification of Defective Response</u> (Identify type of correspondence)				
is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on <u>8/4/06</u> (Date)				
<u>Elizabeth Kinsley</u> (Typed or Printed Name of Person Mailing Correspondence)				
 (Signature of Person Mailing Correspondence)				
Note: Each paper must have its own certificate of mailing.				
<div></div>				



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/537,852	Steven Paul Boneham	87792.065605

INTERNATIONAL APPLICATION NO.

PCT/GB03/05436

I.A. FILING DATE

12/12/2003

PRIORITY DATE

12/12/2002

23469

JAECKLE FLEISCHMANN & MUGEL, LLP
 190 Linden Oaks
 ROCHESTER, NY 14625-2812

RECEIVED

APR 24 2006

CONFIRMATION NO. 7202

371 FORMALITIES LETTER



OC000000018574100

Date Mailed: 04/20/2006

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.** Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*


PAULETTE R KIDWELL

Telephone: (703) 308-9140 EXT 216

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/537,852	PCT/GB03/05436	87792.065605

FORM PCT/DO/EO/922 (371 Formalities Notice)



TRANSMITTAL LETTER
(General - Patent Pending)

Docket No.
87792.065605

In Re Application Of: Boneham et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/537,852	December 12, 2005	Unknown	23,469	1646	7267

Title: **PEPTIDE PRESENTATIONS FOR HUMAN IMMUNODEFICIENCY VIRUS VACCINES**

COMMISSIONER FOR PATENTS:

Transmitted herewith is:

Submission of Papers Previously Filed in the U.S. Patent and Trademark Office in Response to a Notification of Defective Response

in the above identified application.

- ☐ No additional fee is required.
- ☐ A check in the amount of _____ is attached.
- ☐ The Director is hereby authorized to charge and credit Deposit Account No. _____ as described below.
 - ☐ Charge the amount of _____
 - ☐ Credit any overpayment.
 - ☐ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Dated: _____

Signature


I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

(Date)

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence

CC: _____



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/537,852	Steven Paul Boneham	87792.065605

INTERNATIONAL APPLICATION NO.

PCT/GB03/05436

I.A. FILING DATE

PRIORITY DATE

12/12/2003

12/12/2002

23469
JAECKLE FLEISCHMANN & MUGEL, LLP
190 Linden Oaks
ROCHESTER, NY 14625-2812

RECEIVED

MAR 29 2006

CONFIRMATION NO. 7202

371 FORMALITIES LETTER



OC000000018350323

Date Mailed: 03/24/2006

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495)

- Indication of Small Entity Status
- Priority Document
- Copy of the International Application filed on 06/08/2005
- Copy of the International Search Report filed on 06/08/2005
- Preliminary Amendments filed on 06/08/2005
- Information Disclosure Statements filed on 12/12/2005
- Oath or Declaration filed on 12/12/2005
- Request for Immediate Examination filed on 06/08/2005
- U.S. Basic National Fees filed on 06/08/2005
- Priority Documents filed on 06/08/2005
- Power of Attorney filed on 12/12/2005
- Specification filed on 12/12/2005
- Claims filed on 12/12/2005
- Abstracts filed on 12/12/2005

DOCKETED
Response due 4/24/06
By: ELC

Applicant's response filed 12/12/2005 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 10/13/2005 have not been completed.

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.** Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825

(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

PAULETTE R KIDWELL

Telephone: (703) 308-9140 EXT 216

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/537,852	PCT/GB03/05436	87792.065605



PATENT
Serial No. 10/537,852 (87792.065605)
Submission of Papers Previously Filed

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicants:	Boneham et al.)	Examiner: Unknown
)	
Serial No.:	10/537,852)	Art Unit: 1646
)	
Filed:	December 12, 2005)	Confirmation No.: 7267
)	
For:	PEPTIDE PRESENTATIONS FOR)	
	HUMAN IMMUNODEFICIENCY)	
	VIRUS VACCINES)	
)	

**SUBMISSION OF PAPERS PREVIOUSLY FILED IN THE U.S. PATENT
AND TRADEMARK OFFICE IN RESPONSE TO A NOTIFICATION OF
DEFECTIVE RESPONSE**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed in Exhibit A is a copy of the papers mailed to the PTO on April 21, 2006 in response to a notification of defective response together with a stamped return receipt postcard.

The attorney shown below talked with Ms. Paulette R. Kidwell of the PTO on August 4, 2006 by telephone. She said that they had not received a response, and that we should send a copy of the papers filed and a copy of the return receipt postcard. She also indicated that there should not be any time extension fees due.

The enclosed response was in response to a Notification of Defective Response dated April 24, 2006 which required a response within one month with no extension of time possible. The enclosed response was mailed (with a certificate of

mailing by first class mail) on May 21, 2006. Applicants' attorney received in one envelope a Withdrawal of Previously sent Notice and a Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures dated May 20, 2006. These two papers were received on May 24, 2006, which was past the deadline for responding to the Notification of Defective Response dated April 24, 2006. Copies of these two papers with applicants' attorney's date stamp are enclosed in Exhibit B.

Since applicants had submitted the documents required by both the Notice of Defective Response dated April 24, 2006 and the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures dated May 20, 2006, the documents required by the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures dated May 20, 2006 had already been submitted when the applicants' attorney actually received the Notification dated May 20, 2006.

Please accept our response of May 21, 2006, a copy of which is enclosed, as our response to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures dated May 20, 2006.

Applicants do not believe that any fee is due at this time. However, the
Commissioner is hereby authorized to charge any fees that may be due to Deposit
Account No. 10-0223.

Respectfully submitted,

Dated: AUGUST 4, 2006

Robert D. Lott
Robert D. Lott
Reg. No. 28,441

JAECKLE FLEISCHMANN & MUGEL, LLP
190 Linden Oaks
Rochester, New York 14625-2812
Tel: (585) 899-2930
Fax: (585) 899-2931

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

Applicant(s): Boneham et al.

Docket No.

87792.065605

Application No.

10/537,852

Filing Date

December 12, 2005

Examiner

Unknown


Customer No.

23,469

Group Art Unit

Unknown

Invention: PEPTIDE PRESENTATIONS FOR HUMAN IMMUNODEFICIENCY VIRUS VACCINES



I hereby certify that this Response to Notification of Defective Response (2 pages + 1 duplicate page)
(Identify type of correspondence)

is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on
April 21, 2006
(Date)

Margaret I. Hults

(Typed or Printed Name of Person Mailing Correspondence)

Margaret I Hults

(Signature of Person Mailing Correspondence)

Note: Each paper must have its own certificate of mailing.



Response to Notification of Defective Response mailed March 24, 2006

PATENT

Serial No. 10/537,852 (87792.065605)

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant(s): Boneham et al.)	Examiner: Unknown
)	
Serial No.: 10/537,852)	Art Unit: Unknown
)	
Filed: December 12, 2005)	
)	
For: PEPTIDE PRESENTATIONS FOR)	
HUMAN IMMUNODEFICIENCY)	
VIRUS VACCINES)	
)	

RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Notification of Defective Response mailed March 24, 2006, enclosed are the following:


- 1) Preliminary Amendment;
- 2) Paper Copy of the Sequence Listing;
- 3) Sequence Listing in Computer Readable Form (3.5" diskette);
- 4) Statement in Accordance with 37 C.F.R. § 1.821(f); and
- 5) Copy of the Notification of Defective Response.

Applicants do not believe that any fee is due at this time. However, the Commissioner is hereby authorized to charge any fees that may have been

overlooked to Deposit Account No. 10-0223.

Respectfully submitted,

Dated: 4/21/06



Dennis B. Danella
Reg. No. 46,653

JAECKLE FLEISCHMANN & MUGEL, LLP
190 Linden Oaks
Rochester, New York 14625-2812
Tel: (585) 899-2930
Fax: (585) 899-2931



Remarks

In compliance with the sequence listing rules 37 C.F.R. § 1.821 et seq.,

Applicants have enclosed the following:

1. A computer readable form (CRF) copy of a Sequence Listing in the form of a 3.5" diskette;
2. A paper copy of the Sequence Listing pages 1-30; and
3. A Statement Under 37 C.F.R. § 1.821(f) stating that the content of the paper and computer readable form are the same and include no new matter.

The Sequence Listing has been updated to reflect the proper Applicants and the current/prior application information. No substantive changes have been made to the Sequence Listing, and accordingly no new matter is involved. Applicants respectfully request that the Sequence Listing be entered in the specification and maintain that the application complies with the sequence rules.

Applicants do not believe that any fee is due at this time. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked that may be due to Deposit Account No. 10-0223.

Respectfully submitted,

Dennis B. Danella
Reg. No. 46,653

Dated: 4/21/06

JAECKLE FLEISCHMANN & MUGEL, LLP
190 Linden Oaks
Rochester, New York 14625-2812
Tel: (585) 899-2930
Fax: (585) 899-2931



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/537,852	Steven Paul Boneham	87792.065605

INTERNATIONAL APPLICATION NO.
PCT/GB03/05436

I.A. FILING DATE	PRIORITY DATE
12/12/2003	12/12/2002

23469
JAECKLE FLEISCHMANN & MUGEL, LLP
190 Linden Oaks
ROCHESTER, NY 14625-2812

CONFIRMATION NO. 7202
371 WITHDRAWAL NOTICE

OC000000018573264

Date Mailed: 04/20/2006

WITHDRAWAL OF PREVIOUSLY SENT NOTICE

The Acceptance Notice mailed on 10/13/2005 was sent in error and is hereby withdrawn. A corrected Notice is enclosed. The time period for reply runs from the mail date of the enclosed Notice. We apologize for any inconvenience this caused.

PAULETTE R KIDWELL

Telephone: (703) 308-9140 EXT 216

PART 1 - ATTORNEY/APPLICANT COPY